



*IFW image*

PATENT  
Attorney Docket No. 056291-5205

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: **Patrick PLE** )  
Application No.: **10/533,931** )  
Filed: **May 4, 2005** )  
For: **QUINOLINE DERIVATIVES AS SRC** )  
**TYROSINE KINASE INHIBITORS** )

Confirmation No.: **8039**  
Group Art Unit: **2614**  
Examiner: *Unassigned*

Commissioner for Patents  
U.S. Patent and Trademark Office  
Customer Window, Mail Stop Amendment  
Randolph Building  
401 Dulany Street  
Alexandria, VA 22314

Dated: **July 12, 2006**

Sir:

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)**

**Citation of Technically Related U.S. Patent Applications**

The Examiner's attention is directed to the following technically related U.S. patents or applications of Applicants' assignee:

Inventor	U.S. Serial No. Filing Date	U.S. Patent No. Issue Date	PCT Publication No. PCT Publication Date
Lohmann et al.	08/768,887 December 17, 1996	5,962,458 October 5, 1999	
Thomas et al.	09/125,271 February 10, 1997	6,184,225 February 6, 2001	WO 97/30035 August 21, 1997
Thomas et al.	09/142,339 February 28, 1997	6,291,455 September 18, 2001	WO 97/32856 September 12, 1997
Thomas et al.	09/142,839 March 11, 1997	6,514,971 February 4, 2003	WO 97/34876 September 25, 1997
Thomas et al.	09/180,310 May 2, 1997	6,265,411 July 24, 2001	WO 97/42187 November 13, 1997
Lohmann et al.	09/203,764 December 17, 1996	6,071,921 June 6, 2000	
Thomas et al.	09/254,440 September 23, 1997	6,809,097 October 26, 2004	WO 98/13350 April 2, 1998
Thomas et al.	09/269,595 September 23, 1997	6,414,148 July 2, 2002	WO 98/13354 April 2, 1998

Inventor	U.S. Serial No. Filing Date	U.S. Patent No. Issue Date	PCT Publication No. PCT Publication Date
Thomas et al.	09/486,051 August 19, 1998	6,294,532 September 25, 2001	WO 99/10349 March 4, 1999
Lohmann et al.	09/500,470 February 9, 2000	6,258,951 July 10, 2001	
Hennequin et al.	09/806,836 October 5, 1999		WO 00/21955 April 20, 2000
Lohmann et al.	09/877,005 June 11, 2001	6,362,336 March 26, 2002	
Hennequin et al.	09/913,020 February 8, 2000		WO 00/47212 August 17, 2000
Thomas et al.	10/080,716 February 25, 2002	6,673,803 January 6, 2004	WO 98/13354 April 2, 1998
Thomas et al.	10/129,336 November 1, 2000		WO 01/32651 May 10, 2001
Hennequin et al.	10/220,140 March 1, 2001		WO 01/66099 September 13, 2001
Curwen et al.	10/240,413 April 2, 2001		WO 01/74360 October 11, 2001
Hennequin et al.	10/240,658 April 3, 2001		WO 01/77085 October 18, 2001
Hennequin et al.	10/275,382 November 5, 2002		WO 01/94341 December 13, 2001
Thomas et al.	10/310,074 December 5, 2002		WO 97/34876 September 25, 1997
Hennequin	10/332,274 August 8, 2001		WO 02/12226 February 14, 2002
Hennequin	10/333,592 August 7, 2001	6,887,874 May 3, 2005	WO 02/12228 February 14, 2002
Hennequin	10/343,236 August 8, 2001		WO 02/12227 February 14, 2002
Hennequin et al.	10/344,678 February 14, 2003		WO 02/16352 February 28, 2002
Lambert et al.	10/398,793 April 8, 2003	6,849,625 February 1, 2005	WO 02/30924 April 18, 2002
Lambert et al.	10/399,017 April 10, 2003	6,939,866 September 6, 2005	WO 02/30926 April 18, 2002
Lambert et al.	10/415,053 April 23, 2003		WO 02/34744 May 2, 2002
Ple	10/475,016 October 16, 2003		WO 02/085895 October 31, 2002
Hennequin	10/483,782 January 14, 2004		WO 03/008409 January 30, 2003
Wedge	10/494,704 November 6, 2002		WO 03/039551 May 15, 2003
Hennequin	10/502,538 January 28, 2003		WO 03/064413 August 7, 2003

<b>Inventor</b>	<b>U.S. Serial No. Filing Date</b>	<b>U.S. Patent No. Issue Date</b>	<b>PCT Publication No. PCT Publication Date</b>
Wedge	10/523,832 August 5, 2003		WO 04/014383 February 19, 2004
Wedge	10/523,838 August 5, 2003		WO 04/014426 February 19, 2004
Barge	10/530,567 October 6, 2003		WO 04/032937 April 22, 2004
Barge	10/534,721 May 12, 2005		WO 04/043472 May 27, 2004
Wedge et al.	10/543,106 February 11, 2004		WO 04/071397 August 26, 2004
Thomas et al.	10/698,388 November 3, 2003	6,897,210 May 24, 2005	WO 98/13354 April 2, 1998
Thomas et al.	11/024,840 December 30, 2004		WO 98/13354 April 2, 1998

Where a published US application is not available, the undersigned understands that the text of each related application is essentially the same as the above listed published PCT Application.

Consideration of each listed application is earnestly solicited. A copy of the specification and claims for each application, in the form of the published PCT application from which such application was filed is being filed herewith.

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants petition the Examiner to consider this Information Disclosure Statement and documents listed on the attached Form PTO-1449. To the best of the undersigned's knowledge, this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced Application. Accordingly, Applicants do not believe a fee is due for filing this Information Disclosure Statement.

With the exception of U.S. Patents and published U.S. Applications, copies of the listed documents are attached. Applicants respectfully request that the Examiner initial and return the Form PTO-1449, indicating that the information has been considered and made of record herein.


This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If it should be determined that the listed documents constitute "prior art" under United States law,

Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

**Except** for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully Submitted,  
Morgan Lewis & Bockius LLP



Date: July 12, 2006  
Morgan Lewis & Bockius LLP  
Customer No. 09629  
1111 Pennsylvania Avenue, N.W.  
Washington, D.C. 20004  
Tel. No.: 202-739-3000

By:

Donald J. Bird  
Registration No. 25,323  
Tel. No.: (202) 739-5320  
Fax No.: (202) 739-3001